SUVP.F Stock Overview
Provides bioprocess solutions, and lab products and services worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Sartorius Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €263.10 |
| 52 Week High | €322.00 |
| 52 Week Low | €198.85 |
| Beta | 1.3 |
| 1 Month Change | 32.31% |
| 3 Month Change | n/a |
| 1 Year Change | -9.52% |
| 3 Year Change | -24.69% |
| 5 Year Change | -11.08% |
| Change since IPO | 639.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| SUVP.F | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 32.3% | -4.1% | 0.8% |
| 1Y | -9.5% | -29.5% | 7.2% |
Return vs Industry: SUVP.F exceeded the US Life Sciences industry which returned -26.6% over the past year.
Return vs Market: SUVP.F underperformed the US Market which returned 8.2% over the past year.
Price Volatility
| SUVP.F volatility | |
|---|---|
| SUVP.F Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 11.0% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: SUVP.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine SUVP.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1870 | 13,573 | Joachim Kreuzburg | www.sartorius.com |
Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors; software apps for bioreactors and cell culture shake flasks; fermenters; cell culture media, biolayer interferometry, microbiological testing, and fluid management products; buffers; reagents; plasmids; cellcelector flexs, incubator flowboxes, nanowell arrays, and capillaries and tips; high-throughput screening by cytometry; ultrafiltration solutions; syringe, membrane, glass and quartz microfiber, clarification, syringeless, and in-line filters; and lab chromatography, and filters and blotting papers. It also provides live-cell analysis systems, reagents and consumables, and support and services; live-cell imaging and analysis software; contract manufacturing and integration; OEM membranes and devices, weigh cells, and data analytics; connectivity, and pipetting and dispensing products; electronic and mechanical pipettes, pipette tips, bottle-top dispensers, and pipette controllers and accessories; process automation platform and software, sensors and analyzers, biomolecule analysis tools, and data analytics software; chromatography consumables, columns, and systems; and surface plasmon resonance and process filtration products.
Sartorius Aktiengesellschaft Fundamentals Summary
| SUVP.F fundamental statistics | |
|---|---|
| Market cap | US$16.73b |
| Earnings (TTM) | US$108.75m |
| Revenue (TTM) | US$3.92b |
168.8x
P/E Ratio4.7x
P/S RatioIs SUVP.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SUVP.F income statement (TTM) | |
|---|---|
| Revenue | €3.44b |
| Cost of Revenue | €1.89b |
| Gross Profit | €1.56b |
| Other Expenses | €1.46b |
| Earnings | €95.60m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Jul 22, 2025
| Earnings per share (EPS) | 1.38 |
| Gross Margin | 45.27% |
| Net Profit Margin | 2.78% |
| Debt/Equity Ratio | 115.0% |
How did SUVP.F perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield61%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/07 01:14 |
| End of Day Share Price | 2025/05/05 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sartorius Aktiengesellschaft is covered by 43 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Theresa Dick | Bankhaus Lampe KG |
| Charles Pitman | Barclays |
| Scott Bardo | Berenberg |